Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
The effectiveness of telemonitoring, either self-administered or professionally assisted, in cancer care management: a descriptive, retrospective, observational cohort study.
Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRemote patient monitoring of symptoms is now recommended by International oncology guidelines. In France, knowledge of real-world outcomes using telemonitoring is limited. This real-world French study aimed to evaluate the effectiveness of a telemonitoring solution in patients receiving cancer care.
methodsThe Continuum + Connect solution enables the sending of questionnaires and messages to the oncology team. All patients using the solution between October 1, 2021, and June 30, 2023, were eligible. Patients could respond either by themselves (Self-evaluated [SE]) or with the assistance of homecare nurses (Professionally-assisted [PA]). This retrospective real-world observational cohort study included all patients who started using the Continuum + solution during the study period. Descriptive analyses were performed. Study endpoints included conditions of use, quality of life, medication adherence, and safety outcomes.
resultsOverall, 1,294 patients (SE:19% PA 81%) were included. The mean age was 68.6 years (PA 71.0) and 66.9% were women (PA 63.3%). Most patients (77.3%) received treatment at home, mainly for breast, lung, or renal cancer. Compliance with telemonitoring was satisfactory. No deterioration in quality of life or treatment adherence was observed during the first 3 months of treatment. Overall, 25.3% of patients reported grade 3-4 adverse events, of which only 2.5% represented a deterioration from grade 1-2 to grade 3-4.
conclusionThe Continuum + Connect is feasible and effective for the routine monitoring of symptoms, regardless of the patient's profile. These real-world results provide useful insights and support further research.
Indexed as
Identifiers
41540183What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.